MagPortal.com   Clustify - document clustering
 Home  |  News Feeds  |  Stock Market  |  Newsletter  |  My Articles  |  My Account  |  Affiliate Program  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
See Also
Health
Health / Illness, Injury & Treatments
Health / Medical Practice
Science & Technology / Biology & Life Sciences
Current Medical Articles
The Motley Fool
March 10, 2010
Brian Orelli
Up 160% With Room to Run You've got to love biotech and InterMune. mark for My Articles similar articles
The Motley Fool
March 10, 2010
Brian Orelli
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. mark for My Articles similar articles
The Motley Fool
March 10, 2010
Jennifer Schonberger
A Key Representative Weighs In on Financial Reform and Health Care Paul Kanjorski, D-Pa, talks about what needs to change and what needs to get done on Capitol Hill. mark for My Articles similar articles
The Motley Fool
March 9, 2010
Brian Orelli
Are Billions of Dollars in Revenue at Risk? Vaccine makers' lawsuit protection is called into question. mark for My Articles similar articles
The Motley Fool
March 9, 2010
Brian Orelli
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. mark for My Articles similar articles
The Motley Fool
March 8, 2010
Brian Orelli
Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets. mark for My Articles similar articles
The Motley Fool
March 8, 2010
Brian Orelli
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. mark for My Articles similar articles
The Motley Fool
March 5, 2010
Brian Orelli
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. mark for My Articles similar articles
BusinessWeek
March 4, 2010
Amanda Bennett
Lessons of a $618,616 Death Two years after her husband's death, the author's cover story examines the costs of keeping one man alive to fight in the face of a dismal prognosis. mark for My Articles similar articles
The Motley Fool
March 4, 2010
Brian Orelli
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. mark for My Articles similar articles
The Motley Fool
March 4, 2010
Brian Orelli
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. mark for My Articles similar articles
The Motley Fool
March 3, 2010
Brian Orelli
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. mark for My Articles similar articles
The Motley Fool
March 3, 2010
Brian Orelli
Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration. mark for My Articles similar articles
The Motley Fool
March 2, 2010
Brian Orelli
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. mark for My Articles similar articles
Inc.
March 1, 2010
Kasey Wehrum
The Business of Mission County Hospital A look at the companies that supply the California hospital with virtual records, equipment repair, and laundry services mark for My Articles similar articles
InternetNews
March 1, 2010
Major Tech Firms Back Online Health Care Cisco, Dell, Google, IBM and Microsoft all make news at the major health care show. mark for My Articles similar articles
Chemistry World
February 26, 2010
Sarah Houlton
Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain. mark for My Articles similar articles
The Motley Fool
February 26, 2010
Brian Orelli
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. mark for My Articles similar articles
The Motley Fool
February 26, 2010
Brian Orelli
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. mark for My Articles similar articles
The Motley Fool
February 26, 2010
Brian Orelli
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. mark for My Articles similar articles
The Motley Fool
February 26, 2010
Brian Orelli
Political Theater: More Entertaining Than Helpful Health-care reform, like health-care stocks, remains still stuck in limbo. mark for My Articles similar articles
The Motley Fool
February 26, 2010
Tim Hanson
This Stock Costs Less Than a Sandwich And that makes it a pretty good deal. Female Health Co., a maker of female condoms is still on the AMEX and trading for less than $3 per share. mark for My Articles similar articles
BusinessWeek
February 25, 2010
Weintraub & Tirrell
Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed. mark for My Articles similar articles
The Motley Fool
February 25, 2010
Brian Orelli
Transplanting Future Revenue Bristol-Myers Squibb waits for experts to decide the fate of its kidney cancer drug. mark for My Articles similar articles
The Motley Fool
February 25, 2010
Brian Orelli
13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer. mark for My Articles similar articles
The Motley Fool
February 25, 2010
Brian Orelli
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. mark for My Articles similar articles
The Motley Fool
February 24, 2010
Brian Orelli
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. mark for My Articles similar articles
The Motley Fool
February 24, 2010
Brian Orelli
Medtronic Needs to Regrow a Spine Everything else looks fairly good, but the problem I see involves the slight decline in Medtronic's second-largest segment, spinal products. mark for My Articles similar articles
The Motley Fool
February 23, 2010
Brian Orelli
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. mark for My Articles similar articles
The Motley Fool
February 23, 2010
Brian Orelli
Triple-Teaming Cancer for Fun and Profit Pfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive. mark for My Articles similar articles
The Motley Fool
February 23, 2010
Brian Orelli
The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu. mark for My Articles similar articles
The Motley Fool
February 23, 2010
Brian Orelli
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. mark for My Articles similar articles
The Motley Fool
February 22, 2010
Brian Orelli
A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products. mark for My Articles similar articles
The Motley Fool
February 22, 2010
Brian Orelli
Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light. mark for My Articles similar articles
The Motley Fool
February 22, 2010
Brian Orelli
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. mark for My Articles similar articles
Chemistry World
February 18, 2010
Matt Wilkinson
Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut. mark for My Articles similar articles
Chemistry World
February 4, 2010
Matt Wilkinson
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. mark for My Articles similar articles
CRM
February 2010
Lauren McKay
The New-Age Home Aided by SiteSpect, a specialist in elder-care placement boosts Web conversions and better addresses client needs. mark for My Articles similar articles
Chemistry World
January 28, 2010
Nina Notman
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. mark for My Articles similar articles
Philanthropy
January 1, 2010
Adam Keiper
Breakthrough Medical research is dominated by government and corporate funding. How can philanthropic dollars find a distinctive niche? mark for My Articles similar articles
There are 6379 old articles available for this category.